Semaglutide vs. Tirzepatide in 2026: What the Head-to-Head Evidence Actually Shows

In the only major head-to-head randomized trial completed to date, tirzepatide produced greater average weight loss than semaglutide: 20.2% of body weight over 72 weeks, versus 13.7%. Both medications are FDA-approved for chronic weight management in their brand-name forms, both are prescribed every day across Los Angeles, and both can be the right answer depending on your health history, how your body tolerates them, and your budget. The honest version of "which is better" is more useful than the headline — and it is a decision that belongs with a licensed provider, not a comparison chart.

This is usually the first question people ask once they start seriously considering medical weight management, and 2026 has changed the landscape enough that most older comparisons are out of date: the head-to-head data is now published, the rules around compounded versions have tightened, and the first oral GLP-1 pill for weight management arrived in January. Here is where things actually stand.

What semaglutide and tirzepatide actually are

Semaglutide is a GLP-1 receptor agonist; tirzepatide is a dual-action medication that activates both the GIP and GLP-1 receptors. Both were first developed for type 2 diabetes, both are taken as a once-weekly injection in their original forms, and both work in similar ways: they blunt appetite, slow the rate at which the stomach empties, and support the body's own insulin response, which together make it easier to eat less without the constant negotiation.

The brand names are where people get lost, so it is worth being precise. Semaglutide is sold as Ozempic (approved for type 2 diabetes), Wegovy (approved for chronic weight management, and additionally to reduce the risk of major cardiovascular events in adults with established heart disease and excess weight), and Rybelsus (an oral tablet for type 2 diabetes). In December 2025, the FDA also approved a 25 mg oral form of Wegovy — the first GLP-1 pill for weight management — which began reaching the U.S. market in early 2026. Tirzepatide is sold as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management, plus moderate-to-severe obstructive sleep apnea in adults with obesity). Compounded versions of both compounds also circulated widely during the shortage years; those are a separate category with a very different regulatory status, covered below.

What the head-to-head trial found

SURMOUNT-5, a 72-week randomized trial of 751 adults with obesity or overweight and at least one weight-related condition — but not diabetes — found an average body-weight reduction of 20.2% with tirzepatide versus 13.7% with semaglutide, roughly 50 pounds versus 33 pounds. The full results were published in The New England Journal of Medicine in 2025. Nearly a third of tirzepatide participants (31.6%) lost 25% or more of their body weight, compared with 16.1% on semaglutide, and waist-circumference reductions followed the same pattern.

Two caveats keep those numbers honest. The trial was open-label — participants knew which medication they were taking — and both groups were titrated toward maximum tolerated doses under close supervision, which is not how every real-world program runs. Averages are also just that: plenty of people respond strongly to semaglutide, some respond modestly to either, and no trial figure predicts an individual outcome. For a sense of how progress tends to unfold month by month rather than at week 72, our guide to average GLP-1 weight loss per month walks through the typical curve.

Side effects: more alike than different

The two medications share the same core side-effect profile: gastrointestinal symptoms — nausea, constipation, diarrhea, vomiting — concentrated in the weeks after a dose increase and mostly mild to moderate in trials. In the head-to-head study, GI complaints were the most common adverse events in both groups. Both carry the same class warning based on thyroid C-cell tumors observed in rodent studies, which is why neither is prescribed to anyone with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome, and neither is used during pregnancy.

Tolerability at the individual level is less predictable. Some patients simply feel better on one molecule than the other, and the pace of dose escalation often matters more than the medication chosen — one reason unsupervised dosing is a poor idea, and one reason a provider who adjusts the plan when side effects show up is worth more than the lowest sticker price.

Beyond the number on the scale

The two drugs' FDA labels now differ in ways that can matter more than average weight loss. Brand-name semaglutide (Wegovy) is approved to reduce the risk of heart attack, stroke, and cardiovascular death in adults with established cardiovascular disease and excess weight. Brand-name tirzepatide (Zepbound) became the first medication approved for moderate-to-severe obstructive sleep apnea in adults with obesity. If your history includes heart disease or diagnosed sleep apnea, the "which is better" calculation can flip entirely — which is exactly the kind of judgment a prescribing provider is for.

Cost and access in Los Angeles, 2026

Tirzepatide generally costs more than semaglutide across every channel — insurance, manufacturer self-pay programs, and supervised local programs alike. Insurance coverage for weight management specifically remains inconsistent, and both manufacturers now run direct self-pay channels whose prices have shifted several times in the past year, so it is worth checking current figures rather than trusting a screenshot.

Compounded semaglutide and tirzepatide deserve a clear-eyed note. During the shortage years they were a legal bridge; the FDA declared the tirzepatide shortage resolved in December 2024 and semaglutide's in February 2025, and the broad allowances for compounded copies ended in 2025. Today, FDA's position is that compounded drugs are not FDA-approved and that routine compounding of these medications is limited to narrow circumstances, such as a prescriber documenting a genuine clinical difference for an individual patient. Any program still offering a compounded version should be able to explain, specifically, how it does so and through what licensed pharmacy — ask, and expect a direct answer.

At IV Glow Bar, provider-supervised weight-management programs currently run $300 per month for semaglutide and $425 per month for tirzepatide, beginning with a health intake review and continuing with ongoing provider oversight rather than a vial-and-goodbye transaction. Whether either medication is appropriate for you — and which one — is determined by a licensed provider after that review, not by the menu.

How a provider actually decides

There is no universal winner; there is a right fit for a specific person. The decision usually weighs how much weight loss is clinically meaningful for you, your cardiovascular and sleep-apnea history, how your gut has handled GLP-1 medications before if you have taken them, your budget and coverage, and which medication is realistically sustainable for a year or more. Label criteria for the weight-management brands generally require a BMI of 30 or higher, or 27 and above with at least one weight-related condition — but meeting a number is the beginning of eligibility, not the end of it. And if you are already on one medication and wondering about the other, that conversation belongs with your prescriber; switching involves timing and dose decisions that are not a do-it-yourself project.

Questions patients actually ask

Is tirzepatide just a stronger semaglutide? No. It is a different class of medication — a dual GIP/GLP-1 receptor agonist rather than a GLP-1 alone. The added mechanism appears to contribute to the larger average weight loss seen in trials, but "different" is the accurate word, not "stronger."

Can I switch from semaglutide to tirzepatide, or the reverse? Sometimes, under prescriber management — typically for tolerability problems or a plateau. There is no safe self-serve conversion, and a provider will decide whether a switch, a dose adjustment, or patience is the better move. If you are early in treatment, it helps to know how long these medications usually take to show results before judging a plateau.

Is there a pill instead of injections? As of December 2025, yes: the FDA approved a once-daily 25 mg oral form of semaglutide (Wegovy) for weight management, the first GLP-1 pill with that indication. There is currently no approved oral form of tirzepatide.

Are compounded versions still an option in 2026? Only narrowly. Compounded GLP-1 medications are not FDA-approved, and the broad shortage-era allowances have ended. If a price looks dramatically lower than everything else on the market, that is the first question to ask about.

Talking it through

The most productive next step is not picking a molecule — it is a proper look at your health picture with someone licensed to act on it. Our medical weight-loss assessment takes about two minutes and routes your answers to our clinical team for review; from there, a provider determines eligibility and which program, if any, fits. If you would rather start with a conversation, call or text 310-579-6779 or reach us on WhatsApp, or book a visit — in-clinic on San Vicente Boulevard or by concierge appointment across Beverly Hills, West Hollywood, and the surrounding Westside.

Weight-management care at IV Glow Bar is delivered by our registered nurse under the supervision of our medical director, Dr. Groke, and every program begins with a health intake reviewed by a licensed provider. Meet our licensed providers.

Medical disclaimer: This article is for general information only and is not medical advice. These services are not suitable for everyone; a health intake review is required, and treatment decisions are made by a licensed provider after clinical evaluation. Individual response varies, and no outcome is guaranteed.

Photo courtesy of nilufar nattaq on Unsplash.